Diagnostic Imaging of Chest Wall Tumors
There are several imaging devices routinely utilized for evaluation of chest wall tumors predominantly focused in determining the extent of tumor involvement and the potential for respectability. This comprises computed radiography (CR), ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI), [F-18] FDG positron-emission tomography (PET)/CT, and [F-18] FDG PET/MRI. CR, CT, and MRI are the first line; of these MRI allows tissue characterization, accurate assessment of tumor extent, differentiation from adjacent inflammation, information of blood flow, diffusion capacity, texture features, and specification of metabolites within tumors. Imaging devices are also noninvasive methods which have revolutionized oncological imaging by combination of metabolic activities and morphologic features. They are also useful in guiding biopsy, evaluating patient prognosis, staging the disease, monitoring therapeutic response, and detecting recurrences in chest wall tumors. This leads to the appropriate management of patients with these masses. In vivo morphologic and metabolic information obtained by these several modalities plays an important role to manage patients with chest wall tumors.
KeywordsChest wall tumor Imaging CT MRI PET/CT
This work was supported in part by grants from Scientific Research Expenses for Health and Welfare Programs; the Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare, No. 15K09885; the Scientific Research Expenses for Health and Welfare Programs, No. 29-A-3 (Takashi Terauchi and Ukihide Tateishi: squad leaders); Practical Research for Innovative Cancer Control; and Project Promoting Clinical Trials for Development of New Drugs by Japan Agency for Medical Research and Development (AMED).
- 14.Al-Ibraheem A, Buck AK, Benz MR, Rudert M, Beer AJ, Mansour A, Pomykala KL, Haller B, Juenger H, Scheidhauer K, Schwaiger M, Herrmann K. 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma. Cancer. 2013;119:1227–34.CrossRefPubMedGoogle Scholar
- 16.Tateishi U, Yamaguchi U, Miyake M, Maeda T, Chuman H, Arai Y, Jurik AG, editors. Primary bone tumours. Imaging of the sternocostoclavicular region: Springer-Verlag; 2007. p. 207–28.Google Scholar
- 19.Al-Ibraheem A, Buck AK, Benz MR, Rudert M, Beer AJ, Mansour A, Pomykala KL, Haller B, Juenger H, Scheidhauer K, Schwaiger M, Herrmann K. 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma. Cancer. 2013;119:1227–34.CrossRefPubMedGoogle Scholar
- 23.Sobin LH, Gospodarowicz MK. International Union Against Cancer (UICC): TNM Classification of malignant tumours. 7th ed. New York, NY: Wiley; 2009.Google Scholar
- 25.Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013.Google Scholar
- 28.Tateishi U, Yamaguchi U, Seki K, et al. Glut-1 expression and enhanced glucose metabolism are associated with tumor grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging. 2006;33:683–91.CrossRefPubMedGoogle Scholar
- 41.Uslu L, Asa S, Sager S, Halaç M. Multiple cardiac masses and distant metastatic foci in a patient with high grade pleomorphic sarcoma of the heart revealed by follow-up FDG PET/CT. Nuklearmedizin. 2014;53(2):8–9.Google Scholar
- 43.Schwarzbach MH, Dimitrakopoulou-Strauss A, Mechtersheimer G, Hinz U, Willeke F, Cardona S, Attigah N, Strauss LG, Herfarth C, Lehnert T. Assessment of soft tissue lesions suspicious for liposarcoma by F18-deoxyglucose (FDG) positron emission tomography (PET). Anticancer Res. 2001;21:3609–14.PubMedGoogle Scholar
- 48.Tateishi U, Yamaguchi U, Maeda T, Seki K, Terauchi T, Kawai A, Arai Y, Moriyama N, Kakizoe T. Staging performance of carbon-11 choline positron emission tomography/computed tomography in patients with bone and soft tissue sarcoma: comparison with conventional imaging. Cancer Sci. 2006;97:1125–8.CrossRefPubMedGoogle Scholar
- 50.Buck AK, Herrmann K, Büschenfelde CM, Juweid ME, Bischoff M, Glatting G, Weirich G, Möller P, Wester HJ, Scheidhauer K, Dechow T, Peschel C, Schwaiger M, Reske SN. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine. Clin Cancer Res. 2008;14:2970–7.CrossRefPubMedGoogle Scholar
- 51.Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, Chin LK, Hofstrand PD, Grierson JR, Eary JF, Krohn KA. [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30:695–704.CrossRefPubMedGoogle Scholar
- 53.Eiber M, Takei T, Souvatzoglou M, Mayerhoefer ME, Fürst S, Gaertner FC, Loeffelbein DJ, Rummeny EJ, Ziegler SI, Schwaiger M, Beer AJ. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions. J Nucl Med. 2014;55:191–7.CrossRefPubMedGoogle Scholar